期刊
NEUROLOGIC CLINICS
卷 29, 期 2, 页码 435-+出版社
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1016/j.ncl.2011.01.003
关键词
Alemtuzumab; Daclizumab; BG-12; Fumarate; Cladribine; Fingolimod; Laquinimod; Teriflunomide
资金
- Bayer Schering Healthcare
- Biogen-Idec
- Five Prime Therapeutics
- Genzyme
- GlaxoSmithKline
- GW Pharma
- Ironwood Pharmaceuticals
- Merck-Serono
- Novartis
- Protein Discovery Laboratories
- Roche
- Teva-Aventis
- Vertex Pharmaceuticals
- UCB Pharma
- Pfizer
- Merz
Until recently, interferon beta and glatiramer acetate were the only licensed disease-modifying therapies for relapsing forms of multiple sclerosis. These agents have a modest effect on reducing relapse rates. The licensing of two more effective agents, mitoxantrone and natalizumab, provided alternatives. These agents are associated with potentially life-threatening or serious side effects. In addition, none of these licensed agents has been shown to be effective in primary progressive MS. There is a large unmet need, with several promising new therapies in the pipeline. This article reviews the proposed mechanisms of action of the anticipated treatments, their efficacy, and risks associated with their use.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据